Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Effect of FTY720 on the SET–PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Perrotti D, Neviani P . Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol 2013; 14: e229–e238.

    Article  CAS  Google Scholar 

  2. Cristobal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, Odero MD . PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 2011; 25: 606–614.

    Article  CAS  Google Scholar 

  3. Cristobal I, Garcia-Orti L, Cirauqui C, Cortes-Lavaud X, Garcia-Sanchez MA, Calasanz MJ et al. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica 2012; 97: 543–550.

    Article  CAS  Google Scholar 

  4. Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest 2013; 123: 4144–4157.

    Article  CAS  Google Scholar 

  5. Estella Hermoso-de Mendoza A, Castello-Cros R, Imbuluzqueta E, Cirauqui C, Pippa R, Odero MD et al. Lipid nanosystems enhance the bioavailability and the therapeutic efficacy of FTY720 in acute myeloid leukemia. J Biomed Nanotechnol 2014; in press.

  6. Agarwal A, Mackenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW et al. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res 2014; 20: 2092–2103.

    Article  CAS  Google Scholar 

  7. Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, Vitek MP . Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene 2011; 30: 2504–2513.

    Article  CAS  Google Scholar 

  8. Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G et al. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood 2013; 122: 1923–1934.

    Article  CAS  Google Scholar 

  9. Saito S, Miyaji-Yamaguchi M, Shimoyama T, Nagata K . Functional domains of template-activating factor-I as a protein phosphatase 2A inhibitor. Biochem Biophys Res Commun 1999; 259: 471–475.

    Article  CAS  Google Scholar 

  10. Arnaud L, Chen S, Liu F, Li B, Khatoon S, Grundke-Iqbal I et al. Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET. FEBS Lett 2011; 585: 2653–2659.

    Article  CAS  Google Scholar 

  11. Yu G, Yan T, Feng Y, Liu X, Xia Y, Luo H et al. Ser9 phosphorylation causes cytoplasmic detention of I2PP2A/SET in Alzheimer disease. Neurobiol Aging 2013; 34: 1748–1758.

    Article  CAS  Google Scholar 

  12. Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med 2013; 5: 105–121.

    Article  CAS  Google Scholar 

  13. Christensen DJ, Ohkubo N, Oddo J, Van Kanegan MJ, Neil J, Li F et al. Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J Immunol 2011; 186: 2535–2542.

    Article  CAS  Google Scholar 

  14. Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood 2013; 122: 3034–3044.

    Article  CAS  Google Scholar 

  15. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007; 117: 2408–2421.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Dr Bachs for the GST-SET FL and Dr Ye for the GST-SET 1–77, 1–127, 1–177 and 1–227 fragments. This study was supported by Ministerio de Ciencia e Innovación (PI11/02443), Departamento Salud del Gobierno de Navarra (78/2012), ISCIII-RTICC (RD12/0036/0063) and Fundación para la Investigación Médica Aplicada (Spain).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M D Odero.

Ethics declarations

Competing interests

DJC and MPV are shareholders (>5%) and employees of Oncotide Pharmaceuticals, Inc. The remaining authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pippa, R., Dominguez, A., Christensen, D. et al. Effect of FTY720 on the SET–PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity. Leukemia 28, 1915–1918 (2014). https://doi.org/10.1038/leu.2014.141

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2014.141

This article is cited by

Search

Quick links